Indoco Remedies Q1 FY27 Unaudited Results: Revenue Up 6% YoY to ₹408.1 Crore, EBITDA ₹42.2 Crore
Indoco Remedies reported Q1 FY27 unaudited results. Standalone revenue grew 6% YoY to ₹408.1 Crore. EBITDA improved significantly to ₹42.2 Crore from ₹14.8 Crore YoY. Consolidated revenue was ₹467.5 Crore. The company recognized an exceptional gain of ₹97.34 Crore from the sale of its Ophthalmic Business Division. Management highlighted steady progress in domestic and international businesses.
The results show year-on-year growth and improved profitability, which are positive indicators. However, the consolidated results and specific segment performance details are not extensively elaborated in the provided text to warrant a 'HIGH' impact. The exceptional gain is a one-time event.
The company reported a year-on-year increase in revenue and a significant improvement in EBITDA, indicating positive business performance. The managing director's commentary also reflects a positive outlook on the company's strategy and business segments.
Indoco Remedies Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors, in their meeting held on July 28, 2026, approved these results along with the Limited Review Report from their statutory auditors, Gokhale & Sathe, which contained an unmodified opinion.
The company reported standalone revenue from operations of ₹40,812 Lakhs (₹408.12 Crore) for the quarter, a 6% increase from ₹38,561 Lakhs (₹385.61 Crore) in the same quarter last year. Standalone EBITDA for the quarter stood at ₹422 Lakhs (₹4.22 Crore), a significant improvement from ₹148 Lakhs (₹1.48 Crore) in the prior year's comparable quarter, with EBITDA to net sales at 10.3% compared to 3.8% year-on-year.
Consolidated revenue from operations was ₹46,750 Lakhs (₹467.50 Crore) for the quarter. The company also recognized an exceptional item of ₹9,734 Lakhs related to the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited.
Ms. Aditi Panandikar, Managing Director, commented that the Q1 FY27 results reflect the continued execution of the company's long-term strategy, driven by the resilient Domestic Formulation business, while international formulations and API businesses showed steady progress. The company has a global presence with 10 manufacturing facilities (6 for FDFs and 4 for APIs) and a strong brand portfolio in various therapeutic segments.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.